Target Genetic Abnormalities for the Treatment of Colon Cancer and Its Progression to Metastasis | Bentham Science
Promising results for a new bowel cancer treatment
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C | NEJM
KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy
IJMS | Free Full-Text | Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
Study reveals potential target for precision colorectal cancer treatment - Redox Medicine Society
Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX | Scientific Reports
Sotorasib shows activity in advanced colorectal cancer with KRAS G12C mutation
KRAS testing is a screening of non-responders to anti-EGFR therapy.... | Download Scientific Diagram
Life | Free Full-Text | Integrated Decision-Making in the Treatment of Colon -Rectal Cancer: The Case of KRAS-Mutated Tumors
The current treatment paradigm for patients with metastatic colorectal... | Download Scientific Diagram
Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer | Pharmacogenomics
Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients | Nature Communications
Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer | Semantic Scholar
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer | Molecular Cancer | Full Text
Colorectal Cancer
TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers - ScienceDirect
Frontiers | Targeting KRAS: The Elephant in the Room of Epithelial Cancers
RAS mutations: impact on treatment outcome | Colorectal Cancer
Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. | Semantic Scholar
Colorectal Cancer – Treatments | Gastrointestinal Cancer
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis - The Lancet Oncology
Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
Cells | Free Full-Text | KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study
Clinical characteristics and prognostic value of the KRAS mutation in Chinese colorectal cancer patients - Ye Yuan, Yingting Liu, Ye Wu, Junling Zhang, Chunti Shen, Feng Zhang, Changping Wu, Wenwei Hu, 2021
